Icatibant Avansor (Icatibant)

Icatibant is a competitive antagonist of the bradykinin B2 receptor. By blocking this receptor, it prevents bradykinin‑induced vasodilation and vascular permeability, which are key drivers of the swelling seen in hereditary angioedema.

The dose of icatibant is determined by the prescribing clinician based on the patient’s condition and regulatory guidelines. The medication is administered as a subcutaneous injection, and the prescriber will specify the exact dosing regimen.

Safety of icatibant in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and import documentation.

Icatibant is a bradykinin B2 receptor antagonist, whereas other approved HAE therapies include C1‑esterase inhibitor concentrates and kallikrein inhibitors. Icatibant offers a subcutaneous route and rapid onset of action, making it convenient for self‑administration during acute attacks.

Icatibant Avansor must be stored at 2‑8 °C (refrigerated). Keep the product in its original packaging, protect it from light, and do not freeze or shake the vial before use.

Icatibant is supplied as a solution for injection and is given subcutaneously, typically into the abdomen or thigh. The injection is performed by a trained healthcare professional or by the patient after appropriate instruction.

Serious risks include severe hypersensitivity reactions such as anaphylaxis, laryngeal edema that can compromise the airway, and profound hypotension. Patients should be monitored closely after injection, and any signs of severe reaction require immediate medical attention.

Icatibant is contraindicated in individuals with known hypersensitivity to icatibant or any component of the formulation. Caution is also advised for patients with uncontrolled hypertension, severe renal impairment, or those taking ACE inhibitors without appropriate monitoring.